[{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Macrogenics Chief Scott Koenig Details the Upbeat Cancer Drug Data from 2 Programs That Drove a Big Spike in their Share Price","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Publication Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$900.0 million","upfrontCash":"$150.0 million","newsHeadline":"MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Publication of Flotetuzumab Interim Phase 1\/2 Clinical Trial Results in Blood","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Flotetuzumab Publication in Blood Advances","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces FDA Approval of MARGENZA\u2122 for Patients with Pretreated Metastatic HER2-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Zai Lab","pharmaFlowCategory":"D","amount":"$1,455.0 million","upfrontCash":"$55.0 million","newsHeadline":"MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Provention Bio","pharmaFlowCategory":"D","amount":"$395.0 million","upfrontCash":"Undisclosed","newsHeadline":"MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,760.0 million","upfrontCash":"$60.0 million","newsHeadline":"Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Synaffix","pharmaFlowCategory":"D","amount":"$586.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Inks $586m Deal with MacroGenics to Enable Next Generation ADCs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Synaffix","pharmaFlowCategory":"D","amount":"$2,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Announces Expansion of ADC Collaboration with MacroGenics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$900.0 million","upfrontCash":"$150.0 million","newsHeadline":"MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ\u2122 (retifanlimab-dlwr)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by MacroGenics
Under the agreement, Incyte has obtained exclusive worldwide rights for the development and commercialization of Zynyz (retifanlimab-dlwr) in all indications, while MacroGenics retained the right to develop its pipeline assets in combination with Zynyz.
Under the agreement, MacroGenics gained access to Synaffix's clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads, each designed to enable ADCs with best-in-class efficacy and tolerability.
MGD019 (lorigerlimab) is a bispecific IgG4-based, Fc-bearing DART molecule that was designed to enhance blockade on PD-1 and CTLA-4 dual-expressing, tumor-infiltrating lymphocytes, while maintaining maximal PD-1 blockade on all circulating PD-1-expressing cells.
Lead Product(s):
Lorigerlimab,Vobramitamab Duocarmazine
Under the terms of the agreements held in 2018, Provention has acquired all rights to Tzield (teplizumab) to be further developed as PRV-031 and licensing rights to MGD010 for development as PRV-3279.
The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
MGA271 (enoblituzumab) is an investigational anti-B7-H3 monoclonal antibody that incorporates an immunoglobulin G1 fragment crystallizable (Fc) domain designed to enhance Fcγ receptor-mediated antibody-dependent cellular cytotoxicity.
Under the licensing agreement, MacroGenics will gain access to Synaffix’s clinical stage GlycoConnect™ antibody conjugation technology, HydraSpace™ polar spacer technology, as well as select toxSYN™ linker-payloads for the discovery of Antibody-drug Conjugate.
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules. MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms and a lead research program targeting solid tumors.
Lead Product(s):
Bispecific Antibody-based Therapy
Under its exclusive global collaboration and license agreement with Incyte. Retifanlimab is an investigational anti-PD-1 monoclonal antibody designed by MacroGenics and licensed to Incyte.
MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® (trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial.